Hot News

Marking a New Milestone in Overseas Markets Henliu’s HLX02, the First China-developed Trastuzumab Biosimilar Receives Marketing Authorization Application for Review from EMA

Henlius trastuzumab biosimilar HLX02 has been accepted by the European Medicines Agency (EMA) for reviewing its Marketing Authorization Application (MAA) . HLX02 has established three “Firsts” both in China and globally. First China biosimilar conducted a multi-center, international phase 3 clinical trial First trastuzumab developed in China following the National Medical Products Administration (NMPA) technical guideline for biosimilar with the New Drug Application (NDA) received the acceptance for review from the NMPA First China-developed trastuzumab biosimilar accepted for MAA review by the EMA

Hot News

Fosun Pharma’s Innovative Drug ORIN1001 Receives U.S. FDA Fast Track Designation, Marking a Milestone for the treatment of Triple-negative Breast Cancer

SHANGHAI, June 16, 2019-Shanghai Fosun Pharmaceutical (Group) Co., Ltd.(“Fosun Pharma; stock code: 600196.SH, 02196.HK))...

Hot News

Releases its 2018 Annual Corporate Social Responsibility Report Fosun Pharma sustains to meet its CSR commitment for 11 Consecutive Years

On March 25, 2019, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Fosun Pharma”, stock...

Hot News

Fosun Pharma Releases 2018 Annual Results：Adhere to Innovation and Internationalization with Steady Growth in Pharmaceutical Manufacturing and R&D segment Revenue RMB 24.92 billion, up 34.45% YOY Cash flows from operating activities RMB 2.95 billion, up 14.34% YOY R&D Investment RMB 2.51 billion, up 63.92% YOY

On 25 March 2019, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (Fosun Pharma, stock code：600196.SH，02196.HK), a leadin...